International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLD: Clues From the PTLD-1 Trial
| Autor: | Trappe, R.U. *, Choquet, S., Dierickx, D., Mollee, P., Zaucha, J.M., Dreyling, M.H., Dührsen, U., Tarella, C., Shpilberg, O., Sender, M., Salles, G., Morschhauser, F., Jaccard, A., Lamy, T., Reinke, P., Neuhaus, R., Lehmkuhl, H., Horst, H.A., Leithäuser, M., Schlattmann, P., Anagnostopoulos, I., Raphael, M., Riess, H., Leblond, V., Oertel, S. |
|---|---|
| Zdroj: | In American Journal of Transplantation April 2015 15(4):1091-1100 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Plný text